- AAN PREVIEW: Oral drugs make a case for surpassing biologics in MS
- US FDA delays Biogen MS drug BG-12 by 3 months
- Teva agrees SPA for third Phase III MS laquinimod trial
- Lagging rivals, Teva eyes more studies of MS pill
ONLY 0 DAY LEFT
|Stay close to your market. Renew online now to ensure uninterrupted access to:|
|SCRIP Intelligence's news and expert commentary|
|Market Data and Company Analysis (SCRIP 100, SCRIP Asia 100)|
|The Ask the Analyst Service...and more.|
Please remember to quote your order number and customer number.
You can also renew by calling: +44 (0)20 7017 5540.